On July 16, DexCom rose 5.6% in regular trading, reaching $77.46/share with turnover of $55.71 million. The rally was driven by a dual catalyst of an analyst price target upgrade and a recent regulatory approval in Canada.

Truist raised its price target on DexCom to $87 from $80, maintaining a Buy rating. The mean analyst target now stands at approximately $86.04 according to FactSet consensus. Additionally, on July 14, Health Canada authorized DexCom's G7 15 Day continuous glucose monitoring system for adults aged 18 and older with diabetes. The device provides real-time glucose readings for up to 15.5 days, making it the longest-lasting CGM authorized in Canada. The product is not yet commercially available, with launch details pending.

The broader Health Care Equipment sector showed strength, with Abbott Laboratories up 12.4%, Stryker up 5.73%, Boston Scientific up 5.23%, and Medtronic up 5.11%. DexCom is scheduled to report Q2 earnings on July 30, with consensus EPS estimate at $0.61.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)